AKT1 and hepatocellular carcinoma: Silencing RBM39 has been shown to suppress PI3K/AKT activity in hepatocellular carcinoma (HCC) and acute myeloid leukemia (AML), leading to impaired cell proliferation and tumor growth [42,43].